JUMPCAN(SH:600566) Xin Lang Zheng Quan·2025-07-07 09:23Core Insights - Hubei Jichuan Pharmaceutical announced that its subsidiary received a marketing license acceptance notice for its pediatric constipation granules, marking a significant development in the pediatric medicine sector [1][5]. Company Summary - Jichuan Pharmaceutical has invested approximately 51.41 million yuan in the development of pediatric constipation granules, which are based on a patented formula from a pediatrician at Capital Medical University [3]. - The company, established in 1997, holds a market value of 23.8 billion yuan and is recognized as a national high-tech enterprise and a key enterprise in the National Torch Program [6]. - In the first quarter of 2025, Jichuan reported a revenue of 1.525 billion yuan, a year-on-year decline of 36.51%, indicating pressure on its traditional business model and the urgent need for transformation [6]. Industry Summary - There are currently no similar prescription drugs for pediatric constipation available in China, highlighting a significant market gap that the pediatric constipation granules aim to fill [5]. - The pediatric medication market is characterized by a lack of innovative drugs, presenting a substantial opportunity for growth as health awareness increases and population demographics shift [6][7]. - The Chinese pharmaceutical industry is transitioning from a "follower" to a "runner" phase, with increasing support for traditional Chinese medicine innovation from government policies [7].